Abecma (idecabtagene vicleucel)

Numéro de dossier de l’APP: 21655
État des négociations:
Under consideration for negotiation
Indication(s):
For the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment
Promoteur/fabricant:
Celgene Inc.
Numéro de projet de l’ACMTS:
PG0240
Lettre-contrat de l’APP:
Not Applicable
Conclusion du processus de négociation:
Not Applicable